ArticleiScience2025
Quantitative single-cell imaging suggests increased global chromatin accessibility in tumor versus non-tumor cell lines.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nucleosome spacing across cell types, diseases, and ages.Nucleic acids research · 2026Review
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
Cancer phenotypic plasticity is associated with poor prognosis. The mechanisms of phenotypic plasticity are not fully understood. Possibly, the degree of chromatin accessibility defines the easiness of cell transitions between phenotypes. To test this, a method to compare chromatin accessibility between cells is needed. We propose to measure the chromatin accessibility of a cell by total signal from nuclei stained with DNA-binding fluorescent molecules. This method is based on data that some small molecules bind nucleosome-free DNA better than nucleosomal DNA. Thus, fluorescence of these molecules is proportional to the amount of nucleosome-free DNA, serving as a measure of chromatin accessibility. We optimized the method using several DNA-binding molecules and known chromatin modulating agents. Using a set of tumor and non-tumor cells we observed the higher chromatin accessibility of tumor versus non-tumor cells. Chromatin accessibility was also increased upon oncogene-induced transformation of mouse and human cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.